Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. uri icon

authors

  • Li, Daneng
  • Winer, Eric P
  • Tripathy, Debu
  • Schneider, Bryan
  • Barry, William
  • Dickler, Maura N
  • Hurria, Arti
  • McCall, Linda M
  • Hahn, Olwen M
  • Hudis, Clifford A
  • Cohen, Harvey J
  • Muss, Hyman B
  • Jatoi, Aminah
  • Lafky, Jacqueline M
  • Ballman, Karla V

publication date

  • January 1, 2018